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Abstract
Aim. To study the location of pravastatin, simvastatin, fluvastatin and cerivastatin in molecular
complexes with model cell membranes based on dodecylphosphocholine, and also to calculate
the average interatomic distances between the atoms of statins and micelles. Material and
methods. Nuclear magnetic resonance (NMR) spectroscopy was chosen as a method of study.
NMR spectroscopy of  the Overhauser  nuclear  effect  (NOESY)  is  one of  the most  effective
methods  in  the  study  of  intermolecular  interactions,  in  particular,  in  studies  of  drugs.
Information on the spatial structure of the molecular complex, as well as on the fragments of
molecules responsible for the effective interaction leading to complex formation, was obtained
by NOESY spectroscopy.  All  NMR experiments were performed on a Bruker  Avance II  500
spectrometer with a 5 mm zgradient inverse sensor with the TOPSPIN software. The calculation
of the interatomic distances was made with an accuracy of 0.1 Å. Results. The location of
pravastatin, simvastatin, fluvastatin and cerivastatin in molecular complexes with model cell
membranes  based  on  dodecylphosphocholine  was  determined  based  on  NMR  NOESY
experiments. The average interatomic distances between the atoms of statins and micelles
were also calculated. Pravastatin weakly binds to the polar surface of the model membrane,
while simvastatin penetrates into the space between the hydrocarbon chains of the micelle.
Fluvastatin interacts mainly with model membranes by penetration of its aromatic fragments
into the surface of the micelle. Cerivastatin has a unique arrangement in the model membrane.
It is located deep in the hydrophobic nucleus of the micelle close to the terminal methylene
group. Conclusion: Even minor differences in the chemical structure of statins lead to different
patterns of interaction with model membranes. These differences can explain the characteristics
of the pharmacological properties of these substances.
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